Atai Beckley N.V. (ATAI) is one of the best debt-free penny stocks to buy now. CEO Srinivas Rao highlighted progress in pipeline development and corporate foundation after the company joined the NASDAQ Biotechnology Index. The company raised $300 million to advance clinical programs and partnered with Beckley Psytech in mental health therapeutics.

The redomiciliation of Atai Beckley’s parent company from a Netherlands entity to a U.S. entity is expected to save costs and streamline reporting. ATAI is a clinical-stage biopharmaceutical company focusing on mental health treatments, including psychedelic and non-psychedelic compounds for depression and anxiety. CEO Rao is optimistic about future value for patients and shareholders.

While ATAI shows investment potential, other AI stocks may offer greater upside with less risk. For an undervalued AI stock with benefits from Trump-era tariffs, check out the free report on the best short-term AI stock. Explore more investment opportunities with the 10 Best Blue Chip Stocks for 2026 and the 10 Best Metal Stocks to Buy Right Now. No disclosure in the article.

Read more at Yahoo Finance: Atai Beckley N.V. (ATAI) Achieves Significant Milestone on Pipeline Development and Corporate Foundation